Abstract
Inflammation plays a central role in chronic obstructive pulmonary disease (COPD). COPD related inflammation is less responsive to inhaled steroids compared to asthma. There are three major novel anti-inflammatory approaches to the management of COPD. The first approach is phosphodiesterase inhibitors, such as roflumilast which provides additional clinical benefit either as a single agent or as an additive treatment to long-acting bronchodilators. The second approach involves novel strategies using drugs licensed for other indications, such as statins and macrolides; limited prospective studies on these strategies exist at the moment. A third potential approach involves novel agents whose mechanism of action is closely related to COPD mechanisms and pathophysiology. Such novel treatments are of great interest since they may treat both COPD and co-morbidities. Several novel agents are currently under development and may be of importance in the future.
Keywords: Systemic inflammation, COPD, anti-inflammatory agents, statins, macrolides, phosphodiesterase inhibitors
Current Drug Targets
Title:Novel Anti-Inflammatory Agents in COPD: Targeting Lung and Systemic Inflammation
Volume: 14 Issue: 2
Author(s): Stelios Loukides, Konstantinos Bartziokas, Jorgen Vestbo and Dave Singh
Affiliation:
Keywords: Systemic inflammation, COPD, anti-inflammatory agents, statins, macrolides, phosphodiesterase inhibitors
Abstract: Inflammation plays a central role in chronic obstructive pulmonary disease (COPD). COPD related inflammation is less responsive to inhaled steroids compared to asthma. There are three major novel anti-inflammatory approaches to the management of COPD. The first approach is phosphodiesterase inhibitors, such as roflumilast which provides additional clinical benefit either as a single agent or as an additive treatment to long-acting bronchodilators. The second approach involves novel strategies using drugs licensed for other indications, such as statins and macrolides; limited prospective studies on these strategies exist at the moment. A third potential approach involves novel agents whose mechanism of action is closely related to COPD mechanisms and pathophysiology. Such novel treatments are of great interest since they may treat both COPD and co-morbidities. Several novel agents are currently under development and may be of importance in the future.
Export Options
About this article
Cite this article as:
Loukides Stelios, Bartziokas Konstantinos, Vestbo Jorgen and Singh Dave, Novel Anti-Inflammatory Agents in COPD: Targeting Lung and Systemic Inflammation, Current Drug Targets 2013; 14 (2) . https://dx.doi.org/10.2174/1389450111314020008
DOI https://dx.doi.org/10.2174/1389450111314020008 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
Call for Papers in Thematic Issues
New drug therapy for eye diseases
Eyesight is one of the most critical senses, accounting for over 80% of our perceptions. Our quality of life might be significantly affected by eye disease, including glaucoma, diabetic retinopathy, dry eye, etc. Although the development of microinvasive ocular surgery reduces surgical complications and improves overall outcomes, medication therapy is ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
1,2,3-Triazine Scaffold as a Potent Biologically Active Moiety: A Mini Review
Mini-Reviews in Medicinal Chemistry Recombinant Secretory Immunoglobulin A in Passive Immunotherapy: Linking Immunology and Biotechnology
Current Pharmaceutical Biotechnology New Strategies in the Chemotherapy of Leukemia: Eradicating Cancer Stem Cells in Chronic Myeloid Leukemia
Current Cancer Drug Targets The Many Roles of Chemokine Receptors in Neurodegenerative Disorders: Emerging New Therapeutical Strategies
Current Medicinal Chemistry Patent Selections
Recent Patents on Inflammation & Allergy Drug Discovery Production of 68Ga-citrate Based on a SnO2 Generator for Short-Term Turpentine Oil-Induced Inflammation Imaging in Rats
Current Radiopharmaceuticals Binding Interactions of Forskolin with Human Serum Albumin: Insights from In silico and Spectroscopic Studies
Current Chemical Biology Non-Peptidic Inhibitors of Cysteine Proteases
Mini-Reviews in Medicinal Chemistry Mast Cells as Targets of Pimecrolimus
Current Pharmaceutical Design Patent Selections
Recent Patents on Inflammation & Allergy Drug Discovery Edible Transgenic Plant Vaccines for Different Diseases
Current Pharmaceutical Biotechnology Biological Significance of Polymorphism in Legume Protease Inhibitors from the Bowman-Birk Family
Current Protein & Peptide Science Topomer CoMFA and Virtual Screening Studies of Azaindole Class Renin Inhibitors
Combinatorial Chemistry & High Throughput Screening Patents on Therapeutic and Cosmetic Applications of Bioactives of Crocus Sativus L. and their Production through Synthetic Biology Methods: A Review
Recent Patents on Biotechnology Role of Breathing Exercises and Yoga/Pranayama in Childhood Asthma: A Systematic Review
Current Pediatric Reviews Synthesis of pyridyl benzimidazoles encompassing 4-thiazolidinone derivatives as potential antimicrobial agents
Letters in Drug Design & Discovery Mitochondrial Biogenesis: Regulation By Endogenous Gases During Inflammation and Organ Stress
Current Pharmaceutical Design Inflammation Theories in Psychotic Disorders: A Critical Review
Infectious Disorders - Drug Targets Anaphylaxis: An Update on its Understanding and Management
Recent Patents on Inflammation & Allergy Drug Discovery Hypersensitivity Reactions to Anticoagulant Drugs
Current Pharmaceutical Design